Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | MMP14 | P50281 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 11/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75038 | 0.88 | ACACB (0.50) | MMP13MMP14ACACB | |
| SCHEMBL8536867 | 0.81 | CCR5 (0.40) | EPHX2 | |
| SCHEMBL4101596 | 0.80 | GPR119 (0.53) | EPHX2 | |
| SCHEMBL4111969 | 0.78 | EPHX2 (0.49) | EPHX2 | |
| SCHEMBL8530303 | 0.77 | LPL (0.47) | ACACBLIPE | |
| SCHEMBL4111964 | 0.77 | APP (0.42) | ACACB | |
| SCHEMBL20985185 | 0.76 | KDM4E (0.46) | ACACB | |
| SCHEMBL4718944 | 0.76 | HRH1 (0.47) | — | |
| SCHEMBL74340 | 0.75 | GPR119 (0.60) | MMP13MMP14LIPE | |
| SCHEMBL28053867 | 0.73 | OPRK1 (0.41) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129412-B2 | Hydantoin derivatives useful as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-1828166-B1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| EP-1828166-A1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064218-A1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | MMP3, MMP9, MMP2 | MMP13 13/4885MMP14 10/4885ACACB 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.